## SUPPLEMENTAL DATA (Figures S1-S4)





**Figure S1 related to Figure 1:** *Pax8-rtTA-mediated inactivation of VhI* induces hepatic *Epo* but not renal *Epo*. (A) Stabilization of HIF- $\alpha$  in *VhI<sup>-/-</sup>* tubular epithelial cells and hepatocytes. Shown are representative photographs of HIF-1 $\alpha$  and HIF-2 $\alpha$  immunohistochemistry in renal cortex, renal medulla, and livers from P8;*VhI<sup>fl/fl</sup>* and Cre<sup>-</sup> control mice. Strong nuclear HIF-1 $\alpha$  staining was detected in both renal cortex and medulla, whereas strong nuclear HIF-2 $\alpha$  staining was predominantly found in the renal cortex compared to renal medulla (weak staining). Strong HIF-2 $\alpha$  staining was also detected in a subset of hepatocytes, which is consistent with hepatic *Epo* induction. Arrowheads indicate HIF-1 $\alpha$  or HIF-2 $\alpha$  expression in renal epithelial cells or hepatocytes; stars depict glomeruli; arrows denote renal interstitial cells. (B) Ablation of *VhI* in REPC results in *Epo* induction. Shown are relative *Epo* mRNA levels were normalized to *18S* ribosomal RNA. Asterisks indicate a statistically significant difference when comparisons were made to the control group using the unpaired 2-tailed Student's t-test; \*\*\* *P* < 0.001. Shown are mean values ± SEM. Scale bars correspond to 200 µm. *Abb.*: Co, Cre<sup>-</sup> control littermates.



Figure S2 related to Figure 2: Renal anemia in P8; Vhl<sup>fl/fl</sup>Epo<sup>fl/fl</sup> mice is not associated with structural changes, inflammation, kidney injury or abnormal renal function. (A) Left panel: Shown are blood urea nitrogen (BUN) concentrations from individual P8;  $Vhl^{fl/fl} Epo^{fl/fl}$  and control mice after completion of doxycycline treatment (n = 4 each). Middle panel: Glomerular filtration rate (GFR) as determined by FITC-Inulin clearance in P8; Vhl<sup>fl/fl</sup>Epo<sup>fl/fl</sup> and control mice (n = 3 each). Right panel: Renal blood flow (RBF) by MAG3-scintigraphy in P8;  $Vh^{f^{1/1}} Epo^{f^{1/1}}$  and control mice (n = 4 each). (B) Normal electrolyte concentrations in P8;  $Vh^{f^{1/1}} Epo^{f^{1/1}}$  double mutant mice. Shown are individual values of plasma sodium and potassium concentrations from P8; Vhl<sup>1/H</sup>Epo<sup>fl/fl</sup> and littermate control mice. (C) Representative photographs of H&E stained renal cortex tissue sections from P8; Vhl<sup>fl/fl</sup>Epo<sup>fl/fl</sup> and control mice. No structural anomalies were detected (left upper panel). Representative photographs of CD45 immunohistochemistry of renal cortex tissue sections from P8; $VhI^{t/t}Epo^{t/t}$  and control mice (left lower panel). Semi-quantitative assessment of CD45<sup>+</sup> leukocytes in P8; $VhI^{t/t}Epo^{t/t}$  and control mice (n = 5 each) within one week after completion of doxycycline treatment (right lower panel). Real-time PCR analysis of Kim1, Lcn2, F4/80, II1b, and Tnfa mRNA expression in whole kidney homogenates from P8: Vhl<sup>f//f</sup>Epo<sup>fl/fl</sup> and control mice (n = 5 each) within one week after completion of doxycycline treatment (right upper panel). Relative mRNA expression levels were normalized to 18S ribosomal RNA. Asterisks indicate statistically significant differences compared to control using the unpaired 2-tailed Student's t-test; \* P < 0.05; ns, no significant difference compared to control. Shown are mean values ± SEM. Scale bars correspond to 200 µm. Abb.: Co, littermate control; HPF, high power field.



**Figure S3 related to Figure 3:** The number of EPO-producing cells is reduced in P8;Vhl<sup>fl/fl</sup>Epo<sup>fl/fl</sup> mutants. (A) Top panel: Serum EPO (sEPO) levels in P8;Vhl<sup>fl/fl</sup>Epo<sup>fl/fl</sup> and control (Co) mice at baseline and after phlebotomy (n = 4 each). Lower panel: Renal *Epo* mRNA expression levels in P8;Vhl<sup>fl/fl</sup>Epo<sup>fl/fl</sup> and control mice at baseline and after phlebotomy (n = 3 in the non-phlebotomized control group and n = 4 in the other groups). (B) *Pax8*-rtTA-mediated *Epo* ablation has no effect on renal *Epo* production. Shown are relative renal *Epo* mRNA expression levels normalized to *18S* ribosomal RNA from phlebotomized P8;*Epo<sup>fl/fl</sup>* mutant mice (n = 4), phlebotomized control mice (n = 5), and non-phlebotomized control mice (n = 4). (C) Characterization of mice used for cortical tissue O<sub>2</sub> partial pressure (PtO<sub>2</sub>) measurements. Top panel: Hematocrits (Hct) in P8;Vhl<sup>fl/fl</sup>*Epo<sup>fl/fl</sup>* and control mice (n = 3 each). Lower panel: Arterial O<sub>2</sub> saturation (SaO<sub>2</sub>) from P8;Vhl<sup>fl/fl/fl</sup>*Epo<sup>fl/fl</sup>* and control mice (n = 3 each). Lower panel: Arterial O<sub>2</sub> saturation (SaO<sub>2</sub>) from P8;Vhl<sup>fl/fl/fl</sup>*Epo<sup>fl/fl</sup>* and control mice (n = 3 each). Asterisks indicate a statistically significant difference when comparisons were made to the control group using the unpaired 2-tailed Student's t-test; \*\* *P* < 0.01 and \*\*\* *P* < 0.001; ns, no significant difference compared to control group. Shown are mean values ± SEM.



**Figure S4 related to Figure 6: Recombination analysis and serum EPO levels in P8 mutants.** (**A**) PCR analysis of genomic DNA isolated from kidneys of P8; $VhI^{f/f}Epo^{f/f}$ , P8; $VhI^{f/f}Epo^{f/f}Hif1a^{f/f}$  and P8; $VhI^{f/f}Epo^{f/f}Hif2a^{f/f}$  mutant and littermate control (Co) mice. As previously reported, two different *Hif2a* wild-type (wt) alleles were detected representing a polymorphism in the *Hif2a* allele (1). (**B**) Linear relationship between serum EPO (sEPO) levels (log scale) and corresponding hematocrits (Hct) in P8; $VhI^{f/f}Epo^{f/f/f}$  (heterozygously deficient for *VhI*) and littermate control mice. Hematocrit and sEPO values from P8; $VhI^{f/f}Epo^{f/f/f}$  p0<sup>f/f/f</sup>Epo<sup>f/f/f</sup> and P8; $VhI^{f/f}Epo^{f/f/f}$  mice are shown in the same graph. *Abb.*: 2-lox, non-recombined conditional allele; 1-lox, recombined allele.

## **References:**

1. Rankin EB, Rha J, Unger TL, Wu CH, Shutt HP, Johnson RS, Simon MC, Keith B, Haase VH. Hypoxiainducible factor-2 regulates vascular tumorigenesis in mice. *Oncogene*. 2008;27(40):5354-5358.